Request Your Free White Paper Now:

"Unlocking the Future of Bispecific Antibody Production"

Download this White Paper to Learn More

Bispecific and multispecific antibodies represent a transformative class of therapeutics, offering dual-targeting capabilities for enhanced efficacy in oncology and other indications. However, their structural complexity introduces significant challenges in design, manufacturability, and cost-effective production. This white paper outlines Just – Evotec Biologics’ integrated approach to overcoming these hurdles through advanced technologies and continuous bioprocessing.

Key Highlights:

• Market Potential: Bispecific antibodies are projected to grow at >26% CAGR (2023–2028), outpacing monospecific antibodies fivefold.
• Design Optimization: AI/ML-driven Abacus™ platform enables in silico manufacturability assessments, stability predictions, and immunogenicity risk evaluation.
• Cell Line Development: Proprietary J.CHO™ High Expression System and inducible GS KO CHO-K1 lines deliver high titers (approximately 3 g/L) and >92% purity.
• Analytical Excellence: Multi-Attribute Method (MAM) and high-throughput analytics ensure early detection of mispaired species and critical quality attributes.
• Intensified Manufacturing: Perfusion-based upstream processes achieve titers up to 18 g/L equivalent, with >70% aggregate reduction and >80% HCP clearance compared to fed-batch production.
• Sustainability & Quality: Continuous capture and detergent-based viral inactivation enhance product stability and environmental safety.

By integrating AI/ML-driven molecular design, analytics, and intensified manufacturing, Just – Evotec Biologics accelerates development and unlocks the full clinical potential of bispecific therapeutics.

Offered Free by: Evotec
See All Resources from: Evotec